Pluvicto
FDA Expands Pluvicto Indication to Earlier Line of Treatment for PSMA-Positive Prostate Cancer
Prostate cancer patients who have not yet received chemotherapy are now eligible for treatment with Pluvicto.
Real-World Studies Aim to Optimize Treatment Sequence for Novartis' Pluvicto in Prostate Cancer
Premium
Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.
Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto
During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.
The firm presented early data for a blood-based approach to screen prostate cancer patients for PSMA, which it believes has advantages over PET imaging.
CMS Rolling Out New Payment Policy for High-Cost Diagnostic Radiopharmaceuticals
The government payor said it will separately pay for specialized diagnostic radiopharmaceuticals without transitional pass-through payment status.
Jul 18, 2024